CARDIOVASCULAR [bdsy]
Selective Estrogen Receptor Modulators [horm, phsu]
coronary artery disease [dsyn]
Main [qlco]
Mortality [qnco]
postmenopausal [tmco]
Women [popg]
Menopause [phsf]
estrogen deficiency [dsyn]
Metabolic [ftcn]
vascular [bpoc]
consequences [ftcn]
coronary artery disease [dsyn]
Hormone Therapy [topp]
Reported [inpr]
Metabolic [ftcn]
vascular factor [aapp]
coronary artery disease [dsyn]
Observational Study [resa]
Reported [inpr]
Hormone Therapy [topp]
coronary artery disease [dsyn]
Clinical Trials, Randomized [inpr, resa]
WHI [inpr]
Question [inpr]
Efficacy [qlco]
Hormone Therapy [topp]
Primary [qlco]
Secondary Prevention [topp]
coronary artery disease [dsyn]
confirming [qlco]
Lipid [lipd]
lowering [spco]
Hormone Therapy [topp]
WHI [inpr]
Increased [qnco]
Interest [menp]
GIVEN [cnce]
Action [ftcn]
Selective Estrogen Receptor Modulators [horm, phsu]
Cardiovascular system [bdsy]
Chemical Structure [inpr]
Selective Estrogen Receptor Modulators [horm, phsu]
Tamoxifen [orch, phsu]
benzothiophene [orch]
Raloxifene [orch, phsu]
derivatives [chvs]
Estrogens [horm, phsu, strd]
Selective Estrogen Receptor Modulators [horm, phsu]
molecules [sbst]
Bind [acty]
Affinity [npop]
Selective Estrogen Receptor Modulators [horm, phsu]
Conformational change [moft]
Ligand Binding Domain [amas]
modulate [spco]
Ability [orga]
Proteins [aapp, bacs]
Relative [famg]
Balance [orgf]
Cell [cell]
Transcriptional [genf]
activity [dora]
receptor complex [celc]
Ligand [chem]
Selective Estrogen Receptor Modulators [horm, phsu]
Estrogen [horm, phsu, strd]
Agonist [phsu]
Estrogen Effect [fndg]
Antagonist [ortf]
depend [medd]
Tissue [tisu]
Targeted [ftcn]
Selective Estrogen Receptor Modulators [horm, phsu]
Variable [qlco]
effects [qlco]
Metabolic [ftcn]
vascular factor [aapp]
coronary artery disease [dsyn]
Selective Estrogen Receptor Modulators [horm, phsu]
Reported [inpr]
modulate [spco]
lipid lipoprotein [aapp, lipd]
Profile [lbpr]
Toremifene [orch, phsu]
Raloxifene [orch, phsu]
HMR 3339 [strd]
Raloxifene [orch, phsu]
Decrease [qlco]
Serum homocystine level [lbpr]
c reactive proteins [aapp, imft]
Marker [clna]
Coronary Artery Disease Risk [inpr]
Raloxifene [orch, phsu]
Reported [inpr]
Nitric Oxide [bacs, inch, phsu]
Endothelin-1 [aapp, bacs]
Ratio [qnco]
Contribute [acty]
Endothelial [tisu]
function [phsf]
Vasodilation [phsf]
Toremifene [orch, phsu]
Nitric Oxide [bacs, inch, phsu]
Endothelin-1 [aapp, bacs]
Ratio [qnco]
Raloxifene [orch, phsu]
Decrease [qlco]
Vascular Cell Adhesion Molecule [aapp, imft]
Inflammatory [ftcn]
Cytokines [aapp, imft]
tnf alpha [aapp, imft]
IL6 [aapp, imft]
Selective Estrogen Receptor Modulators [horm, phsu]
Raloxifene [orch, phsu]
Extensive [qlco]
Evaluation [ftcn]
Blood vessel wall [bpoc]
Endothelium [tisu]
confirmed [qlco]
Large [qnco]
Clinical Trials [resa]
Raloxifene [orch, phsu]
Reported [inpr]
cohesion [npop]
Intercellular junction [bsoj]
VE-cadherin [aapp, imft]
synthesis [biof]
degradation [ftcn]
Extracellular Matrix [tisu]
MMP-2 [aapp, enzy]
Multiple [qnco]
outcomes study [resa]
Raloxifene [orch, phsu]
Evaluation [ftcn]
Reported [inpr]
Raloxifene [orch, phsu]
Administered [ftcn]
postmenopausal [tmco]
Women [popg]
High Risk [qlco]
coronary artery disease [dsyn]
